Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]        
Net Sales $ 1,107,418 $ 1,227,247 $ 1,531,880 $ 2,868,275
Cost of Sales 329,246 700,977 532,602 2,038,919
Gross Profit 778,172 526,270 999,278 829,356
Operating expenses        
Compensation and related expenses 243,956 475,056 602,444 715,511
Professional fees 121,952 125,359 221,584 194,674
Marketing expenses 289,070 299,870
General and administrative expenses 348,671 79,487 475,843 177,899
Total operating expenses 1,003,649 679,902 1,599,741 1,088,084
Operating (Loss) (225,477) (153,632) (600,463) (258,728)
Change in fair value of derivative liability 922,022 873,830
Interest (expense) (250) (2,750) (649,607) (5,813)
Net Income (Loss) 696,295 (156,382) (376,240) (264,541)
Net (loss) income attributable to noncontrolling interests (41,194) 43,594 (68,924) (2,516)
Net Income (loss) attributable to Immudyne, Inc. $ 737,489 $ (199,976) $ (307,316) $ (262,025)
Basic income (loss) per share attributable to Immudyne, Inc. $ 0.02 $ (0.01) $ (0.01) $ (0.01)
Diluted income (loss) per share attributable to Immudyne, Inc. $ 0.02 $ (0.01) $ (0.01) $ (0.01)
Average number of common shares outstanding        
Basic 40,849,638 32,338,946 39,224,839 32,174,661
Diluted 47,254,218 32,338,946 39,224,839 32,174,661